ALK-abello A/S Class B (DE:4AJ0)
FRANKFURT:4AJ0
4AJ0 Stock Chart & Stats
€28.16
-€0.22(-1.06%)
At close: 4:00 PM EST
€28.16
-€0.22(-1.06%)
Day’s Range― - ―
52-Week Range€23.68 - €36.14
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€8.05B
Enterprise Value€45.97B
Total Cash (Recent Filing)€316.00M
Total Debt (Recent Filing)€990.00M
Price to Earnings (P/E)46.8
Beta0.26
Next Earnings
Aug 20, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.28
Shares Outstanding202,567,200
10 Day Avg. Volume17
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.81Price Target Upside44.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ALK-abello News
4AJ0 FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest stock price was €23.68 and its highest was €36.14 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is €8.05B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on May 04, 2026. The company reported €0.267 earnings per share for the quarter, beating the consensus estimate of €0.227 by €0.04.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Undervalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B does not currently pay dividends.
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate is 0.2.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of €0.267 in its last earnings report, beating expectations of €0.227. Following the earnings report the stock price went up 7.276%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in DE:4AJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ALK-abello A/S Class B
ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
4AJ0 Company Deck
4AJ0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company delivered strong Q1 financial results (18% revenue growth, 22% EBIT growth, 32% EBIT margin), achieved a major tablet sales milestone (over DKK 1 billion in a quarter), upgraded full-year guidance, reported robust regional and anaphylaxis product growth, and announced a successful Phase II peanut trial and key neffy regulatory approvals. Notable challenges include higher capacity costs (+23%), international shipment phasing (notably Japan) causing a -17% tablet decline in some markets, partner-related lower-margin revenue expected to rise, neffy market-access hurdles (UK local formularies, U.S. access), potential German pricing/rebate risk, and planned increased R&D/commercial spending for upcoming phases. Overall, the positives materially outweigh the negatives given upgraded guidance, cash generation, and strategic clinical progress.View all DE:4AJ0 earnings summaries4AJ0 Stock 12 Month Forecast
Average Price Target
€40.81
▲(44.91% Upside)
Technical Analysis
ALK-abello
―
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol-Myers Squibb
―
Options Prices
Currently, No data available
---